Brain Tumor News!


Note: The comments under each article title are the opinion of our president, Al Musella, DPM,
and do not reflect official policy of the Musella Foundation!
Displaying Stories 2121 to 2140 of 7,674
Previous 20           Next 20


04/18/14 "Brain Tumor Forum" patient conference        

 From our friends at the Monmouth and Ocean County Brain Tumor Support Group



04/16/14 ERGO: A pilot study of ketogenic diet in recurrent glioblastoma.        

   This is a small trial of the ketogenic diet with and without Avastin, and it didn't help at all, however, this is not the same low calorie ketogenic diet that has shown some promise.  



04/16/14 Additive homeopathy in cancer patients: Retrospective survival data from a homeopathic outpatient unit at the Medical University of Vienna.        

This is a perfect example of how you can use statistics incorrectly to make anything look good.  The inclusion group was defined as patients who had at least 3 homeopathic consults in 4 years.  If you take any group of cancer patients and only count those that lived 4 years, of course they are going to show better results.  This doesn't capture those for whom the treatment did not work.



04/16/14 New Clinical Trials Finder on Virtualtrials.com        

   I am proud of this new feature on the website and would like to thank Stephen Western for his help with the project.  Let me know how you like it and if there is anything we can add to make it better!



04/13/14 Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared to temozolomide-chemoradiation for unresectable glioblastoma. Final results of the TEMAVIR study from ANOCEF.        

 This trial did not show much benefit for using Avastin and Irinotecan for newly diagnosed unresectable GBMs.  There was no difference in overall survival, however, the patients in the control group were able to cross over when the progressed, and there was about a 2 month advantage in time to progression.



04/12/14 Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.        

This is one of the more important articles of the year, and for those of you who love reading highly technical medical literature, well worth reading the entire article (I can not post the full text on virtualtrials.com because of copyright restrictions). This explains how IL13Ra2 works and why it is so important. It also reviews the trials that targeted this and why they failed with hope for future trials.

 As I was reading about the problems of the prior trials, which involved not being able to deliver the drug to the right place using convection enhanced delivery, I thought to presentations from the Tocagen trial which appear to have perfected convection enhanced delivery. I wonder if  they repeated the trials today with the delivery technology from the Tocagen trial, perhaps we would have seen much better results.



04/12/14 Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy        

 This is only 1 patient, and at the time of the report was only 6 months from the start of the treatment, but shows proof of concept that a personalized approach may work. 



04/12/14 Interim Clinical Data for Tocagen's Toca 511 & Toca FC in Patients with High Grade Glioma        

 Good news on the Tocagen Trial.   Safe, well tolerated and early results are better than historical controls.

This is one of my favorites.

Disclaimer:  Tocagen is a small sponsor of our organization, and we are a small sponsor of their clinical trials!



04/12/14 Influenza vaccine immunogenicity in patients with primary central nervous system malignancy.        

 This says that the flu vaccine is not as effective in brain tumor patients as it is in the general population.  It doesn't mean that you shouldn't get the shot, just that it is more important than usual to make sure those around you get it!



04/09/14 IBTA Newsletter        

From our friends at the IBTA.  Sad to see Denis is retiring as Chair of the IBTA.  Kathy Oliver will take his place. Good luck and congratulations to Kathy!



04/09/14 Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study.        

 I am a fan of fractionated stereotactic radiosurgery for GBMs. My sister in law participated in an earlier trial using FSR and a different chemotherapy drug and did very well for about 8 years. She did better than most in that trial but perhaps temodar is a better drug to use along with FSR. 



04/08/14 Integrin Inhibitor Suppresses Bevacizumab-Induced Glioma Invasion.        

 When I first heard about the drug Cilengitide, I thought it would be perfect to use with a treatment like Avastin.  I hope to see human trials of this soon.  My thoughts:  as shown in this article, Avastin cuts off the blood supply to the tumor, and stops a new blood supply from forming, so the only way the tumor can survive is to invade surrounding areas looking for a new blood supply.  It makes sense to combine it with a drug that stops that invasion.



04/06/14 Researchers successfully treat brain tumor with sound waves        

 This sounds very useful and interesting. Will keep an eye on it



04/04/14 Novocure to Present New Pre-Clinical Data on NovoTTF™ Therapy at the American Association for Cancer Research Annual Meeting 2014        

 Although these 2 abstracts do not involve brain tumors, they show another mechanism of action as to how the Novocure system can work.  The press release doesn't mention it, but the Novocure system IS approved for recurrent glioblastoma multiforme.

Disclosure:  The Novocure company is a sponsor of our organization.



04/03/14 Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors.        

 This may be one of the most important articles of the year. It is only in mice, but 100% of the mice were long term survivors. I would love to see this tried in people.



04/03/14 Northwest Bio Warns FDA May Throw Out Phase III Brain Cancer Study        
The source of this article isn't reliable and obviously (from prior articles on the subject) knows little about brain tumors and FDA policy, but he does bring up an important point:
 
Is the endpoint of progression free survival acceptable to get approval for a brain cancer drug?
 
As a member of the "Jumpstarting Brain Tumor Drug Development Coalition" which is based on the National Brain Tumor Society’s Clinical Trial Endpoints Initiative, I recently had the honor of speaking with the FDA about this issue.  The FDA is on our side - we all want to get effective drugs to the people who need them as quickly as possible, while maintaining safety.  The bottom line is that the FDA said that although they prefer the overall survival endpoint,  they would accept progression free survival as an endpoint for approval of a treatment - IF there was a significant benefit to the treatment.  
 
This particular trial is special.  You need a brain tumor surgery to get a tumor sample which is used to make a custom made vaccine to your tumor.  Everyone in the trial gets the vaccine made as well as gets the standard of care.  2/3 of the patients get the vaccine and 1/3 get a placebo.  When the patients in the placebo group have progression of the tumor, they are allowed to cross over into the treatment group and get the vaccine.  This is the most humane way to design a randomized trial; however, it also makes it impossible to judge the treatment on the basis of overall survival.  If the treatment actually works, the overall survivals of both groups would be the same - because both groups get the same treatment so you are comparing the treatment against itself- and the better it works the less chance it would get approved based on overall survival.  The progression free survival endpoint is ideal in this case and is really the only endpoint possible. If they were forced to use overall survival, they couldn’t let the patients cross over, and the custom made vaccine would go to waste – sentencing the patient to an unnecessary death just to make the statistics look better.
 
The question became how much of an improvement is needed in progression free survival to justify approval.  The FDA wouldn't give us a specific answer, but said that if it works, they will approve it. Historically, the FDA will approve a new treatment for incurable diseases if it is just a little better than existing treatments, or the same results as existing treatments with less side effects. The bar is not that high.
 
 
 
 
 


03/30/14 Phase II Trial of 7days on/7 days off temozolmide for recurrent high-grade glioma.        

Looks like we need to find better treatments, although for recurrent anaplastic astrocytoma, it does look promising



03/27/14 Musella Foundation is pleased to receive a $1,000 grant from The Allstate Foundation        

 Thanks to Susan!  I use her for my insurance:)



03/27/14 Inhibitory Effect of Disulfiram/Copper Complex on Non-small Cell Lung Cancer Cells.        

 Although this project was not done for brain tumor cells, it illustrates a very important concept.  I hear of some of our members trying Disulfiram off label to treat their tumors.   There was also a project a while back that tested a copper restriction as a treatment for brain tumors.  So some members combined both.  However this study points out that in lung cancer cells (we do not know if it is true for brain), copper is needed to make the Disulfiram work.

  This points to the need to track people who try these combinations..  this is WHY we run the brain tumor virtual trial. Go to virtualtrials.com and click on Virtual trial for details and to join.  Everyone who has a brain tumor should participate.



03/27/14 Scientists find treatment to kill every kind of cancer tumor        

This is Fox news' take on the next article I am posting!



Displaying Stories 2121 to 2140 of 7674
Previous 20           Next 20